Trials / Terminated
TerminatedNCT05934942
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
An Open-label, Fixed-sequence Cross-over, Two-period, Phase I Trial to Evaluate the Effect of Multiple Doses of BI 1358894 on the Pharmacokinetics of a Combination of Ethinylestradiol and Drospirenone in Healthy Female Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Female
- Age
- 18 Years – 35 Years
- Healthy volunteers
- Accepted
Summary
This study aims to investigate the effect of multiple doses of BI 1358894 on pharmacokinetics of ethinylestradiol (EE) and drospirenone (DRSP) (Yasmin®)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Yasmin® | Ethinylestradiol (EE) and Drospirenone (DRSP) |
| DRUG | BI 1358894 | BI 1358894 |
Timeline
- Start date
- 2023-09-08
- Primary completion
- 2024-02-08
- Completion
- 2024-02-08
- First posted
- 2023-07-07
- Last updated
- 2025-02-24
- Results posted
- 2025-02-24
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05934942. Inclusion in this directory is not an endorsement.